Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-27018966 in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea
Conditions
Interventions
Eluxadoline
Placebo
Locations
288
United States
Furiex Research Site
Anniston, Alabama, United States
Furiex Research Site
Birmingham, Alabama, United States
Furiex Research Site
Birmingham, Alabama, United States
Furiex Research Site
Dothan, Alabama, United States
Furiex Research Site
Huntsville, Alabama, United States
Furiex Research Site
Huntsville, Alabama, United States
Start Date
April 28, 2010
Primary Completion Date
July 14, 2011
Completion Date
July 14, 2011
Last Updated
October 22, 2019
NCT07481422
NCT05740319
NCT07089420
NCT06866106
NCT05293769
NCT03823742
Lead Sponsor
Furiex Pharmaceuticals, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions